Cas:6310-17-4 2-bromo-1-(tert-butyl)-4-nitrobenzene manufacturer & supplier

We serve Chemical Name:2-bromo-1-(tert-butyl)-4-nitrobenzene CAS:6310-17-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-bromo-1-(tert-butyl)-4-nitrobenzene

Chemical Name:2-bromo-1-(tert-butyl)-4-nitrobenzene
CAS.NO:6310-17-4
Synonyms:2-bromo-1-tert-butyl-4-nitro-benzene;1-(tert-butyl)-2-bromo-4-nitrobenzene;2-Brom-1-tert-butyl-4-nitro-benzol;2-BROMO-4-NITRO-1-TERT-BUTYL-BENZENE;benzene,2-bromo-1-(1,1-dimethylethyl)-4-nitro;3-bromo-4-tert-butylnitrobenzene
Molecular Formula:C10H12BrNO2
Molecular Weight:258.11200
HS Code:2904909090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:298ºC at 760 mmHg
Density:1.401g/cm3
Index of Refraction:1.552
PSA:45.82000
Exact Mass:257.00500
LogP:4.17800

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-bromo-1-tert-butyl-4-nitro-benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-bromo-4-tert-butylnitrobenzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-BROMO-4-NITRO-1-TERT-BUTYL-BENZENE Use and application,benzene,2-bromo-1-(1,1-dimethylethyl)-4-nitro technical grade,usp/ep/jp grade.


Related News: Taiwan complained on Sunday that it was being punished because the World Health Organization considers it part of China, which has been subject to travel bans as the coronavirus spreads. 2-bromo-1-(tert-butyl)-4-nitrobenzene manufacturer The victim — who died Saturday — was a 44-year-Chinese man who flew in from Wuhan in January. 2-bromo-1-(tert-butyl)-4-nitrobenzene supplier Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity. 2-bromo-1-(tert-butyl)-4-nitrobenzene vendor In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say. 2-bromo-1-(tert-butyl)-4-nitrobenzene factory Physiologically relevant interactions with test molecules or protein ligands can be identified with high sensitivity and specificity.